In patients diagnosed with FLT3-mutated AML, there is evidence that FLT3 inhibitors are an effective adjunctive therapy intended to induce CR, progression to allogenic hematopoietic stem cell transplantation, and remission maintenance after transplantation. Here, FLT3 is linked to acute myeloid leukemia.